Background Studies have been published showing both increased and decreased utilization of cancer screening services in cancer survivors compared with cancer-free counterparts. This study synthesizes existing evidence in a meta-analysis.
Background
The utilization of cancer screening programs in the USA is suboptimal. Currently, screening rates are~58% for colorectal, 73% for breast and 81% for cervical cancer screening. 1 These rates are far below targets set by the Healthy People 2020 initiative: 71% for colorectal, 81% for breast and 93% for cervical cancer screening. 2 Among all subpopulations receiving cancer screening, cancer survivors are of special interest. Besides their high susceptibility for cancer recurrence, cancer survivors have an increased risk for new primary cancers and illnesses other than cancer. [3] [4] [5] Focusing on screening behavior among cancer survivors could shed light on how to improve screening utilization among survivors as well as the general population. However, it is unclear whether screening utilization among cancer survivors differs from that of their cancer-free counterparts.
There are controversial theories, suggesting that cancer survivors are either less or more likely to receive screening services and preventive care than cancer-free controls. 6, 7 Screening behavior of cancer survivors may be influenced by decisions made by their health care providers, as well as their individual experiences. Frequent contact and familiarity with the health care system may increase the willingness of cancer survivors to meet cancer screening recommendations for new primary cancers. On the other hand, survivors might suffer emotionally and financially from their diagnosis, thus decreasing screening practices. 8 Prior cancer diagnosis might also shift the attention of health care professionals away from further screening measures. 9 Two previous systematic reviews have examined this topic, reporting conflicting results. A systematic review by Wilkins et al. 10 concluded that cancer survivors were less likely to adopt secondary prevention practices than cancer-free controls. Conversely, a systematic review and metaanalysis by Corkum et al. 11 reported that cancer survivors received more frequent screening for new primary cancers compared with cancer-free controls. 11 However, these reviews combined heterogeneous groups of childhood and adulthood cancer survivors, and included prostate cancer screening, currently rated evidence Grade D by the United States Preventive Services Task Force (USPSTF). 12 In addition, studies were included that did not differentiate between screening for new primary cancers and follow-up procedures in cancer survivors. Finally, several large epidemiological studies have been published in recent years, advancing the insight on screening utilization in cancer survivors.
Thus, in this paper we systematically reviewed the literature and conducted a meta-analysis of screening utilization for breast, colorectal and cervical cancer comparing cancer survivors with cancer-free controls.
Material and methods
In August 2016, we conducted a systematic literature search related to cancer, cancer survivorship and cancer screening without date and language restrictions. We searched the electronic databases MEDLINE (PubMed) and EMBASE for peer-reviewed observational epidemiological studies based on the search terms and algorithms shown in the Supplementary data. We manually searched the reference lists of previous reviews and included articles to identify additional studies and gray literature. We also contacted preventive care experts at the Harvard T.H. Chan School of Public Health to provide feedback on the search and to help identify additional gray literature.
We included studies if they fulfilled the following criteria: observational study design, adult cancer survivors (not limited to specific cancer type), cancer-free controls and outcome screening utilization. The utilization of cervical, breast and colorectal cancer screenings was evaluated in this study for their relatively high USPTF recommendation rating (Grades A and B). 12 Studies were included if they evaluated the utilization of screening procedures for new primary cancers in cancer survivors. We excluded studies if no discrimination between estimates for follow-up visits and estimates for screening procedures for new primary cancers was possible. For example, studies or subgroups were excluded when reporting on the utilization of mammograms among breast cancer survivors.
We also excluded studies of childhood cancer survivors, studies of secondary survivors such as family members of cancer survivors, studies missing cancer-free control groups, review articles, commentaries and editorials. All reasons for exclusion were documented.
Using a standardized data extraction form, we extracted data on each study's authors, year, study design, data source, cancer and screening ascertainment, inclusion and exclusion criteria, country of study population, types of cancers included, sample size, population characteristics, screening timeframe and odds ratios (ORs) with 95% confidence intervals (CIs).
Quality assessment of each eligible study was done using the Newcastle-Ottawa quality assessment scale (NOS). 13 The scale comprises eight questions grouped under three broad categories: selection of groups, comparability of groups and outcome ascertainment. Study quality was determined on a scale from 0 point (greatest bias) to nine points (least bias). Two authors independently reviewed each study for inclusion, extracted data using the standardized data extraction form and performed a quality assessment using the NOS. Disagreements were discussed and resolved by group consensus.
We conducted overall and separate meta-analyses for breast cancer screening, cervical cancer screening and colorectal cancer screening using STATA, version 13, (StataCorp LP, College Station, TX). We also conducted separate metaregressions, influence and cumulative meta-analyses, sensitivity analyses and tests of publication bias.
All provided ORs compare screening utilization in cancer survivors to cancer-free control groups. For studies presenting crude numbers, we calculated crude ORs and 95% CIs from raw data. For studies that selected cancer survivors as the reference group we inverted the ORs. We chose a random effects model using the DerSimonian-Laird method because of heterogeneity among study designs and populations.
To determine the degree of between-study heterogeneity, we visually assessed forest plots for overlapping CIs and calculated I-squared statistic (95% CI) with associated P-value from χ 2 tests. We conducted subgroup analysis to assess potential sources of heterogeneity based on study characteristics. Subgroups were chosen a priori and included study design (matched case-control versus cross-sectional), cancer type (restricted to breast cancer versus all), ascertainment of screening utilization (self-reported versus claims/record data), control selection (comorbidity matched controls versus others) and study quality (NOS ≥7 versus < 7).
We conducted sensitivity analyses based on inclusion of studies on prostate cancer and assessed the influence of individual studies on the overall effect size via meta-influence analyses. We performed a cumulative meta-analysis to determine whether the pooled effect size changed over time as new studies were published.
For assessment of publication bias, we constructed and visually inspected funnel plots and conducted Egger's tests.
All P-values in this study were two-sided. An alpha level of 0.05 was chosen for statistical significance.
Results

Study selection and characteristics
Through our search of PubMed and EMBASE databases, we identified 3538 publications (Fig. 1) . After screening titles and abstracts, 556 studies were evaluated in full text. We finally included 19 eligible studies in this review. Overall, this review comprises a total of 150 751 cancer survivors and 627 342 cancer-free controls.
The analyses of breast cancer screening from the studies by Bishop et al., Earle et al. and Breslau et al. were excluded since they included breast cancer survivors, and no discrimination between routine follow-up care and screening for new malignancies was possible. [14] [15] [16] The characteristics of the 19 studies included are detailed in Table 1 . Ten studies had matched case-control designs, and nine were cross-sectional. Ten studies reported screening ascertainment using self-reported data such as questionnaires or interviews, seven used insurance claims data and two used patient medical records. Cancer ascertainment was performed using interviews or self-reported data in nine studies, and medical records or cancer registries in 10 studies. Except for two studies from Europe and Asia, all studies evaluated cancer survivors from North America.
Overall, Fig. 2 shows that compared with cancer-free controls cancer survivors were more likely to use cancer screening services (OR = 1.30, 95% CI: 1.20-1.41, P < 0.001).
Similarly, in separate analyses, cancer survivors were more likely to use screening services than cancer-free controls. The pooled estimates were OR = 1.27 (95% CI: 1.13-1.42, P < 0.001) for breast cancer screening, OR = 1.25 (95% CI: 1.15-1.37, P < 0.001) for colorectal cancer screening and OR = 1.38 (95% CI: 1.08-1.75, P < 0.001) for cervical cancer screening. Table 2 shows heterogeneity for each cancer screening procedure (breast, colorectal and cervical) and subgroups by study design, study quality, cancer type, screening ascertainment and control selection. Table 3 shows corresponding pooled estimates and P-values for effect measure modification by subgroups. For breast cancer screening, there was no cancer type subgroup 'restricted to breast cancer', since we excluded these. All cross-sectional studies used self-reported data to ascertain breast cancer screening. All studies evaluating breast and cervical cancer screening were compared with general population controls ('NA').
Subgroup analyses
There was evidence of substantial (50-90%) or considerable (75-100%) between-study heterogeneity except for the breast cancer subgroup in colorectal cancer screening, and the cross-sectional and high study quality subgroups in cervical cancer screening.
We found statistically significant quantitative effect measure modification by study design for breast and colorectal cancer screening. Fig. 1 Flow chart of studies comparing screening utilization in cancer survivors to cancer-free controls. 
SCREENING UTILIZATION AMONG CANCER SURVIVORS
Publication bias
Egger's tests suggested no evidence of publication bias for breast cancer screening studies (P = 0.247), colorectal cancer screening studies (P = 0.564) and cervical cancer screening studies (P = 0.788). There was no asymmetry in the funnel plots upon visual inspection, which are provided in the Supplementary data.
Discussion
Improving the utilization of screening services for malignant diseases is a core issue of public health, since screening rates fail to reach predefined goals. 1,2 Our research focused on the growing population of cancer survivors, for whom studies have been published reporting both increased and decreased screening rates.
Main finding of this study
Overall, we found that cancer survivors were more likely to complete screening for new primary cancers of the breast, colorectum and cervix. Specifically, cancer survivors were 27% more likely to receive breast cancer screening, 25% more likely to receive colorectal cancer screening and 38% more likely to receive cervical cancer screening than cancer-free controls. For these screening services, sensitivity analyses showed consistent direction and magnitude of effects.
Of all included studies, only Aparicio-Ting et al. 17 and Bishop et al.
14 showed point estimates indicating cancer survivors to be less likely to utilize screening services than cancer-free controls. These studies were relatively small, included distinct populations of Hispanic women and leukemic cancer survivors, and utilized self-reported data.
There are several potential mechanisms underlying our findings. As cancer survivors are more familiar with the health care system, they might be more willing to comply with screening recommendations. This is further facilitated by better health insurance of cancer survivors and their frequent visits to primary care physicians and specialists. 32, 33 There are several explanations for the observed effect measure modification by study design and screening ascertainment. First, cross-sectional study designs could lead to larger effect sizes because missing temporality could mask whether cancer survivorship preceded screening usage.
Further, all cross-sectional studies in this analysis were based on survey data with self-reported assessment of the outcomes, increasing the risk for recall bias. For example, the recent, large-scale cross-sectional study by Homan et al. notes that respondents may have reported diagnostic tests rather than screening tests, leading to an overestimation of breast cancer screening rates. 32 
What is already known on this topic
In a prior review article, Corkum et al. 11 reported similar screening patterns to ours, with cancer survivors being 19% more likely to receive breast cancer screening, 22% more likely to receive cervical cancer screening and 19% more likely to receive colorectal cancer screening. However, Wilkins and Woodgate 10 concluded in their review that cancer survivors were less likely to adopt secondary prevention practices than cancer-free controls. Both reviews had limitations, mainly heterogeneous inclusion criteria, and inadequate differentiation between screening utilization for new primary cancers and routine follow-up in cancer survivors.
What this study adds
Our study is the first meta-analysis to evaluate screening utilization in a well-defined cohort of adulthood cancer survivors, excluding potential routine follow-up screenings. Focusing on high evidence rated screening procedures, recent large-scale epidemiological studies were included. We could show that cancer survivors were more likely to utilize screening services than cancer-free controls. Since earlier reviews were contradictory in their results, this study adds important knowledge on a growing population of cancer survivors. 34 
Strengths of this study
Our study has several strengths. First, a robust and sensitive search strategy was used to locate over 3000 articles that were thoroughly screened. Many studies had large sample sizes of up to 150 000 participants, including three recently published large epidemiological studies from 2015 and 2016.
Second, focusing on adult cancer survivors, we excluded childhood cancer survivors, and thereby omitted a significant source of heterogeneity: this strategy is supported by findings of Corkum et al.,
11 who reported small sample sizes and large-scale heterogeneity of publications on childhood cancer survivors.
Third, we restricted our analyses on cancer screenings rated Grades A and B by the USPSTF, offsetting the heterogeneity of our results. 12 Other screening services, including those for prostate and skin cancer, have lower USPSTF ratings and are not always recommended.
Limitations of this study
Our study limitations are mainly inherent to meta-analyses based on observational data including residual confounding and selection bias.
Given the differences in populations, study design, outcome classifications, screening utilization ascertainment and observational time frames across the studies, heterogeneity is expected. Additional variability in the completeness of information by each study may have contributed to the heterogeneity as well.
Another limitation arises from the random effects model we used to pool ORs, which assigns a relatively larger weight to smaller studies. For this concern, statistical solutions are currently under development. 35 Alternatively, a larger weight for large-scale studies could have been achieved using fixed effect models. Yet, we did not consider its strong assumptions to be fulfilled in our analysis cohort. 36 Finally, there are limits to the generalizability of our results, since all but three studies were conducted in the USA, seven of which using Medicare data. Therefore, it is unclear whether the results are generalizable to other health care systems.
Conclusion
In sum, our study indicates that cancer survivors are more likely to use screening services for new primary cancers than their cancer-free counterparts.
Since overall screening rates remain far below targets set by the Healthy People 2020 initiative, investigating the differences of higher uptake groups, such as cancer survivors, can shed light on solutions for the overall population level.
Based on our findings, future studies should evaluate whether an increase in utilization of screening services translates into prolonged survival in cancer survivors.
Furthermore, research should investigate the underlying mechanisms for higher screening utilization in cancer survivors. Targeted public health interventions could then optimize strategies to meet screening targets at the population level.
